



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



UK 122 (trifluoroacetate salt)

Item No. 9001218

CAS Registry No.: 1186653-73-5
Formal Name: 4-[(E)-(5-oxo-2-phenyl-4(5H)-oxazolylidene)methyl]-benzenecarboximidamide, 2,2,2-trifluoroacetate
MF: C₁₇H₁₃N₃O₂ • CF₃COOH
FW: 405.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UK 122 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the UK 122 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. UK 122 (trifluoroacetate salt) is soluble in acetonitrile and methanol.

Description

UK 122 is an inhibitor of urokinase-type plasminogen activator (uPA; IC₅₀ = 0.2 μM).¹ It is selective for uPA over tissue-type plasminogen activator (tPA), trypsin, plasmin, and thrombin (IC₅₀s = >100 μM for all). UK 122 (100 μM) inhibits the migration and invasion of CFPAC-1 pancreatic cancer cells. It prevents glutamate-induced phase shifts in isolated suprachiasmatic nucleus slices from *tPA*^{-/-} but not wild-type mice when used at a concentration of 0.2 μM.² UK 122 (4 mg/kg) decreases disease severity and colorectal levels of RANTES in a mouse model of colitis induced by dextran sulfate (DSS; Item No. 23250).³

References

1. Zhu, M., Gokhale, V.M., Szabo, L., *et al.* Identification of a novel inhibitor of urokinase-type plasminogen activator. *Mol. Cancer Ther.* **6(4)**, 1348-1356 (2007).
2. Cooper, J.M., Rastogi, A., Krizo, J.A., *et al.* Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice. *Eur. J. Neurosci.* **45(6)**, 805-815 (2017).
3. Kida, Y., Okahisa, T., Sato, Y., *et al.* Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice. *Sci. Rep.* **13(1)**, 2899 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM